Article

Bulletproofing Pharma Patents

Authors

With the high cost of drug development, assurance that a pharma company will be able to market a new drug free of generic competition for a long enough period of time to make the initial investment worthwhile is of great importance. Fish Principals Janis Fraser and Christine Goddard recently offered advice to help pharma companies work towards this assurance, giving their six tips for bulletproofing pharma patents in an article they authored for the Life Sciences IP Review newsletter. Get their tips in the full article here.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.